TheraRadar
Data updated: May 26, 2026

DOXEPIN HYDROCHLORIDE

Sleep Approved 1972-01-31

Doxepin tablets are used for patients who struggle with insomnia, specifically those who have trouble staying asleep throughout the night. This medication helps patients with sleep maintenance issues to improve the quality of their rest. It is typically prescribed for durations of up to three months based on clinical evidence.

Source: FDA Label • STRIDES PHARMA INTL

How DOXEPIN HYDROCHLORIDE Works

While the exact way this drug works to maintain sleep is not fully understood, its effects are likely produced by targeting the H1 receptor. By acting as an antagonist at this site, the medication helps patients stay asleep.

42
Indications
--
Phase 3 Trials
54
Years on Market

DOXEPIN HYDROCHLORIDE Approval History

1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
846 FDA actions from 1972 to 2026 · 1 indication expansions
Apr 2026 ORIGINAL
Update
Aug 2025 ORIGINAL
Update
Aug 2024 SUPPL
Label · Labeling

What DOXEPIN HYDROCHLORIDE Treats

1 indications

DOXEPIN HYDROCHLORIDE is approved for 1 conditions since its original approval in 1972. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Insomnia
Source: FDA Label

DOXEPIN HYDROCHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 10 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DOXEPIN HYDROCHLORIDE

3 of 17

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMBIEN
ZOLPIDEM TARTRATE
1 shared
COSETTE
Shared indications:
AMBIEN CR
ZOLPIDEM TARTRATE
1 shared
COSETTE
Shared indications:
BELSOMRA
SUVOREXANT
1 shared
Merck
Shared indications:
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT02062632 results posted MC13C1 NCI-2014-00253, MC13C1 Ph 2 terminated Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
NCT01156142 results posted NCCTG-N09C6 NCI-2011-02049, CDR0000675520 Ph 3 completed Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DOXEPIN HYDROCHLORIDE FDA Label Details

Indications & Usage

FDA Label (PDF)

DOXEPIN HYDROCHLORIDE is indicated for the treatment of Insomnia.

Looking for the branded version?

SILENOR

Full clinical data, patents, trials, and competitive landscape for doxepin hydrochloride.

See SILENOR

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.